Corbus Pharmaceuticals Hldgs Inc (CRBP) Stock Price, Quote & News

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally re...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 963 0100

Fax: 617 663 6085

Website: www.corbuspharma.com

Address:

500 River Ridge Drive, Norwood, United States

shoagh12 Aug. 26 at 4:56 PM

$CRBP dribble up the next weeks

0 · Reply

birdmine Aug. 25 at 7:32 PM

$CRBP hoping to see 12 by the end of the week.

1 · Reply

justme_DC Aug. 25 at 6:39 PM

$GFAI $ICCM $HIVE $CRBP Awesome day!!! Now for goodness sakes...hit us with a nice PR to keep the momentum going!!! Hahummm....no rug pulls!!

0 · Reply

GhostAlchemy Aug. 23 at 10:12 AM

$CRBP Corbus Pharmaceuticals same as CRBD different ticker for same company

0 · Reply

shoagh12 Aug. 22 at 5:31 PM

$CRBP back to 80

0 · Reply

birdmine Aug. 22 at 2:04 PM

$CRBP here we go!! I hope it keeps this momentum!!!

0 · Reply

Cricket23 Aug. 21 at 8:08 PM

$CRBP When this stock wants to move up higher and go on an uptrend, it does it very quickly like we saw today. With all the positive news the company has to report about their valuable pipeline of products we can expect to see $20-30 very soon. Holding Strong!

1 · Reply

birdmine Aug. 21 at 4:24 PM

$CRBP will this ever hit 10$ again?! It’s been in the single digits so long. I’ve forgotten what it looks like in the doubles!!

2 · Reply

RealAvidTrader Aug. 17 at 7:53 PM

💥This Stock Chart Looks BULLISH And Ready To Breakout💥 (Multiple Catalysts) $CRBP $NAGE $CDTX https://youtu.be/nj_Q82gEvE4

0 · Reply

Quantumup Aug. 14 at 8:42 PM

Evercore ISI🏁 $SYKE - says, "We're initiating coverage on $SKYE with an OP rating and $10 PT." $NVO $CRBP Evercore ISI added, "We think nimacimab- the only weekly SC large molecule CB1 inhibitor in development-can fill critical gaps in obesity care: (i) as a GLP-1 off-ramp/maintenance option, (ii) as combo therapy in severe obesity, and (iii) as a non-incretin monotherapy option for select patients. Evercore ISI additionally said:

0 · Reply

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 24, 2025, 4:05 PM EDT - 2 months ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Jun 17, 2025, 3:42 PM EDT - 2 months ago

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

May 22, 2025, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX QURE

Mar 28, 2025, 8:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Feb 14, 2025, 7:30 AM EST - 6 months ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Feb 11, 2025, 7:30 AM EST - 7 months ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Jan 28, 2025, 8:00 AM EST - 7 months ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Jan 6, 2025, 8:00 AM EST - 8 months ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 7:00 AM EST - 9 months ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

$FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer$

Dec 3, 2024, 7:00 AM EST - 9 months ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Nov 11, 2024, 4:12 AM EST - 10 months ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Oct 29, 2024, 8:00 AM EDT - 10 months ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 16, 2024, 8:00 AM EDT - 11 months ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Sep 26, 2024, 8:00 AM EDT - 11 months ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 23, 2024, 2:01 PM EDT - 1 year ago

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Jul 30, 2024, 8:50 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jun 3, 2024, 1:03 PM EDT - 1 year ago

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Jun 1, 2024, 10:00 AM EDT - 1 year ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

May 30, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Feb 28, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 6, 2024, 9:50 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 4:01 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 31, 2024, 9:19 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Jan 30, 2024, 6:55 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Jan 30, 2024, 7:13 AM EST - 1 year ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 29, 2024, 2:17 PM EST - 1 year ago

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Jan 29, 2024, 7:18 AM EST - 1 year ago

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

Jan 26, 2024, 7:30 AM EST - 1 year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Jan 23, 2024, 8:00 AM EST - 1 year ago

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Jan 9, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Dec 18, 2023, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Nov 7, 2023, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023

Sep 27, 2023, 9:05 AM EDT - 2 years ago

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

shoagh12 Aug. 26 at 4:56 PM

$CRBP dribble up the next weeks

0 · Reply

birdmine Aug. 25 at 7:32 PM

$CRBP hoping to see 12 by the end of the week.

1 · Reply

justme_DC Aug. 25 at 6:39 PM

$GFAI $ICCM $HIVE $CRBP Awesome day!!! Now for goodness sakes...hit us with a nice PR to keep the momentum going!!! Hahummm....no rug pulls!!

0 · Reply

GhostAlchemy Aug. 23 at 10:12 AM

$CRBP Corbus Pharmaceuticals same as CRBD different ticker for same company

0 · Reply

shoagh12 Aug. 22 at 5:31 PM

$CRBP back to 80

0 · Reply

birdmine Aug. 22 at 2:04 PM

$CRBP here we go!! I hope it keeps this momentum!!!

0 · Reply

Cricket23 Aug. 21 at 8:08 PM

1 · Reply

birdmine Aug. 21 at 4:24 PM

$CRBP will this ever hit 10$ again?! It’s been in the single digits so long. I’ve forgotten what it looks like in the doubles!!

2 · Reply

RealAvidTrader Aug. 17 at 7:53 PM

💥This Stock Chart Looks BULLISH And Ready To Breakout💥 (Multiple Catalysts) $CRBP $NAGE $CDTX https://youtu.be/nj_Q82gEvE4

0 · Reply

Quantumup Aug. 14 at 8:42 PM

0 · Reply

RadioIsotope25 Aug. 14 at 6:10 PM

$RADX Could turn into to Corbus or MNPR 2.0 with strong data this fall Tiny float $MNPR $CRBP

0 · Reply

TilrayToTheMoon7 Aug. 14 at 1:31 PM

$CRBP can we get above $10 good god. Come get me at $16 please.

0 · Reply

Hepacke Aug. 14 at 1:21 PM

$CRBP

0 · Reply

Hepacke Aug. 14 at 1:16 PM

$CRBP Bullish

0 · Reply

MarkT87 Aug. 14 at 12:36 AM

$CRBP

0 · Reply

Cricket23 Aug. 13 at 4:19 PM

$CRBP The real fun begins once we hit $10! Once we get there, which looks like very soon, all the positive news the company has in their pipeline will send this stock back to its 52 week highs. Holding Strong!

0 · Reply

Estimize Aug. 13 at 10:00 AM

Wall St is expecting -1.72 EPS for $CRBP Q3 [Reporting 11/11 BMO] http://www.estimize.com/intro/crbp?chart=historical&metric_name=eps&utm_c

0 · Reply

birdmine Aug. 12 at 3:27 PM

$CRBP they overplayed their hand when they started dumping shares in the market and killed the momentum. Now the volume is so low daily. I don’t know if it’s ever going to pick up traction.

0 · Reply

ZacksResearch Aug. 8 at 2:01 PM

Cannabis stocks: From boom to bust, but is there hope? 🌱 Once high-flying $TLRY, $CGC, and $GTBIF have seen their valuations crumble under regulatory challenges and persistent federal illegality. The AdvisorShares Pure US Cannabis ETF has plunged 86% in five years, highlighting the prolonged downturn in the industry. 🚨 Find out what's needed for a potential rebound and explore alternative plays like $HRMY and $CRBP in the space 👉 https://www.zacks.com/stock/news/2684137/can-cannabis-stocks-reverse-their-prolonged-downtrend?cid=sm-stocktwits-2-2684137-body-6865&ADID=SYND_STOCKTWITS_TWEET_2_2684137_BODY_6865

0 · Reply

JarvisFlow Aug. 6 at 12:30 PM

Oppenheimer has updated their rating for Corbus Pharmaceuticals ( $CRBP ) to Outperform with a price target of 53.

0 · Reply

Jckemp3 Aug. 5 at 6:32 PM

$CRBP anyone have inflow/outflow numbers ?

0 · Reply

Estimize Aug. 5 at 12:36 PM

$CRBP reported YoY revenue growth for Q2, in Q1. http://www.estimize.com/intro/crbp?chart=historical&metric_name=revenue&utm_content=CRB

0 · Reply

Market Cap	121.20M
Revenue (ttm)	0.00
Net Income (ttm)	-40.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	112,000
Avg Vol	153,998
Day's Range	N/A - N/A
Shares Out	12.26M
Stochastic %K	65%
Beta	3.20
Analysts	Strong Sell
Price Target	$41.00